<DOC>
	<DOC>NCT01129882</DOC>
	<brief_summary>Purpose: To continue to provide aripiprazole intramuscular (IM) Depot treatment (400 mg or 300 mg) to subjects with schizophrenia completing the 52-week, open-label safety and tolerability Study 31-08-248.</brief_summary>
	<brief_title>An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia</brief_title>
	<detailed_description>This is an open-label study which will enroll subjects with schizophrenia completing the 52-week, open-label safety and tolerability Study 31-08-248 and will continue to provide aripiprazole intramuscular (IM) Depot treatment. Subjects can receive this treatment until aripiprazole IM Depot is commercially available in any dosage (including generic formulations) in the country that the study is being conducted or the commercial availability of aripiprazole IM Depot is terminated by the sponsor, or until the study end date of 31 Dec 2018 is reached. Eligible subjects will enter this study at the End of Treatment visit (Week 52) of Study 248. Subjects will continue to receive aripiprazole IM Depot every month (study months are every 4 weeks which is defined as 28 [-2/+10] days) as a continuation of their previous monthly dose in Study 248.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects with a current diagnosis of schizophrenia, as defined by DSMIVTR criteria, who completed the openlabel extension Study 248 (completed Study 248 study completion visit, Week 52). Subjects who, in the investigator's judgment, may benefit from continued participation in an aripiprazole IM Depot study. The baseline visit for Study 270 (which is the Week 52 visit of Study 248) and the first injection for Study 270 must occur within 4 weeks (which is defined as 28 [2/+10] days) of the last injection in Study 248. Subjects who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as require by IRB/IEC), prior to the initiation of any protocolrequired procedures. Subjects able to understand the nature of the study and follow protocol requirements and who can read and understand the written word in order to complete patientreported outcomes measures. Outpatient status. Subjects with a current DSMIVTR diagnosis other than schizophrenia, including schizoaffective disorder, MDD, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder. Subjects who currently meet DSMIVTR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine. Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on the investigator's judgment. Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones. Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening. Electroconvulsive therapy within 180 days prior to entry. Any subject who requires or may need any other antipsychotic medications during the course of the study. Aripiprazole IM Depot (including generic formulation) is commercially available in the subject's country. Other protocol specific inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>